---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-26-000003"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:16.958587+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO

## Summary
- Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).
- Cash and investments $448.3M after repaying $561M convertible notes due Nov 2025.
- Active TTFields patients reached 4,620 globally; Optune Gio prescriptions +6% in Q4.
- Frank Leonard, previously President, appointed CEO in December 2025.
- Filed PMA for TTFields in brain metastases from NSCLC; topline data expected Q1-Q2 2026.

## SEC filing metadata
- accession: 0001645113-26-000003
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000003/0001645113-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000003/nvcr-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-26-000003
- JSON: https://secwatch.observer/filing/0001645113-26-000003.json
- Plain text: https://secwatch.observer/filing/0001645113-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.